Eli Lilly has dominated headlines in recent months, recently taking the crown as the most valuable company in the biopharma ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Viking has identified Neil Aubuchon as the person to oversee its commercial preparations. Aubuchon has joined the biotech as ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. | M+C Saatchi North ...

Trump’s nomination of RFK Jr.—a longtime anti-vaccine activist—to the HHS post less than a year ago signaled the potential ...

Daiichi Sankyo plans to splash out some 300 billion yen ($1.9 billion) on Enhertu manufacturing facilities across the globe, ...